Abiraterone Package Insert

Abiraterone Online Ref - Hospital Authority
Abiraterone online Package Insert – abiraterone (Zytiga®) HK/Zytiga Tab/EU SmPC Nov 2014/LPI May 2015 (Janssen) Cella D, Li S, Lu T et al. Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone ... Get Doc

WHO Pharmaceuticals NEWSLETTER 2
Abiraterone acetate Risk of hypokalaemia, thrombocytopenia and rhabdomyolysis Japan . The Ministry of Health Labour and Welfare (MHLW) and the Pharmaceutical and Medical Devices Agency (PMDA) have announced revisions to the package insert for abiraterone acetate (Zytiga®). Abiraterone acetate is indicated for castration-resistant prostate cancer. ... Read More

Government Health Plan (GHP) Of Puerto Rico Authorization ...
Follow Package insert instructions for dose administration. Section II. References 1. ZYTIGA(R) oral tablets, abiraterone acetate oral tablets. Janssen Biotech, Inc. (per FDA), Horsham, PA, 2016. Section III. Review Log Approved: June 29, 2017 ... Retrieve Here

Proposed Additions And Deletions To The NIOSH Hazardous Drug ...
Proposed Additions and Deletions to the NIOSH Hazardous Drug List 2014 Established Name Proprietary Name Drug Class Formulation(s) Dosage FDA pregnancy Category Drug Package Insert Drugs Recommended by NIOSH to be Added to the 2012 Hazardous Drug List abacavir Ziagen antiviral tablets, oral solution 600mg C PI abiraterone acetate ... Doc Viewer

Summary Of Investigation Results - Pmda.go.jp
Dosage and administration as stated in the package insert of abiraterone acetate. Thrombocytopenia A total of 11 cases of adverse events suggestive of thrombocytopenia have been reported (including 4 cases in which causality could not be ruled out). Rhabdomyolysis No case of adverse events suggestive of rhabdomyolysis has been reported. ... Fetch Here

Yonsa (abiraterone Acetate) - Mediproviders.anthem.com
Yonsa (abiraterone acetate) Override(s) Approval Duration Prior Authorization Quantity Limit 1 year . Medications Quantity Limit Yonsa (abiraterone acetate) May be subject to quantity limit . APPROVAL CRITERIA . Requests for Yonsa (abiraterone acetate) may be approved if the following criteria are met: ... Access Document

Talk:Abiraterone Acetate - Wikipedia
For the “Adverse Effects” section, there is an opportunity to increase the accuracy and completeness of the information available on adverse reactions by referring to the following source: ZYTIGA® (abiraterone acetate) [package insert]. ... Read Article

Hormonal Therapy In The Setting Of CRPC
ZYTIGA® (abiraterone acetate) [package insert]. Horsham, PA: Centocor Ortho Biotech Inc.; 2011. Abiraterone Acetate Adverse Effects • Most AEs occurred during the first 3 months of treatment • Most AEs are grade 1-2 • Most common AEs – Fatigue ... Retrieve Here

Evaluation Of Adherence To Monitoring Parameters For Oral ...
Evaluation of adherence to monitoring parameters for oral chemotherapy agents at an academic medical center Ama Marfo, PharmD; Sally Barbour, PharmD, BCOP, CPP; Ann McGee, PharmD Abiraterone ---Every 2 weeks for first 3 months Methods Baseline Characteristics (N = 92) [package insert] ... Retrieve Content

HIGHLIGHTS OF PRESCRIBING INFORMATION First-Line Non Squamous ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for ... Fetch Here

Pharmaceuticals And Medical Devices Safety Information
Pharmaceuticals and Medical Devices Safety Information No. 321 March 2015 Table of Contents 1. Lamotrigine and Serious Skin Disorders.. 5 2. Abiraterone Acetate and Hypokalaemia administration as stated in the package insert. ... Content Retrieval

PA Notification Zytiga 051818PT - Uhcprovider.com
Zytiga™ (abiraterone acetate) is a CPY17 inhibitor indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer and for high-risk metastatic castration-sensitive prostate cancer. ... Read Content

Clinical Policy: Abiraterone (Zytiga) - Envolve Health
CLINICAL POLICY Abiraterone Page 2 of 3 Background Prostate cancer is estimated to be the most common cancer in men.2 Initial suspicion of prostate cancer is based on an abnormal digital rectal exam or an elevated prostate-specific ... Fetch Full Source

ZYTIGA (abiraterone Acetate) RATIONALE FOR ... - Caremark
ZYTIGA (abiraterone acetate) Zytiga FEP Clinical Rationale times the upper limit of normal (ULN), or the bilirubin rises above three times the ULN, Zytiga ... Doc Viewer

YONSA SUPPORT TM Starter Kit
YONSA® (abiraterone acetate) in combination with methylprednisolone is indicated for the treatment of patients with Package insert for YONSA™ Copy of patient medical records Other supporting documentation PM-US-YON-0017 . ... Get Document

Leanne Schimke MSN, FNP-C, CUNP Certified Urology Nurse ...
• Abiraterone must be taken on an empty stomach. – No food for at least 2 hours before and 1 hour after taking – Food increases absorption by 10-17 times • Do not crush or chew pills. • Need blood work and blood pressure monitored closely. ZYTIGA® (abiraterone acetate) [package insert]. Horsham, PA: Centocor Ortho Biotech Inc.; 2011. ... Doc Retrieval

Oncology Oral Drug Development Challenges And Opportunities
Oncology Oral Drug Development Challenges and Opportunities Mark J. Ratain, MD University of Chicago [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corp.; 2015 Abiraterone $5000 >300% increase $3750 Internal analysis . ... Get Content Here

Abilify Maintena (aripiprazole Extended Release Suspension)
Applies to: Zytiga (abiraterone acetate) Nebraska Family Planning (CHP599) Created 10/2016 Page 1 of 1. Zytiga (abiraterone acetate) Covered uses All medically accepted indications Exclusion Criteria Pregnancy Required Medical Information 1. ... Fetch Doc

Orteronel - Wikipedia
Orteronel (TAK-700) is a nonsteroidal CYP17A1 inhibitor that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result. ... Read Article